2013-10-29T14:53:17-05:00 2013-06-30 410746749 CLIFTONLARSONALLEN LLP 1301 W 22ND ST STE 1100 OAK BROOK IL 60523 990 2012-07-01 731386920 GATEWAY FOR CANCER RESEARCH GATE 8473427450 1336 BASSWOOD ROAD SCHAUMBURG IL 60173 RICHARD J STEPHENSON 5473427450 2013-10-15 1 GREGORY S ADAMS P00095597 6305738600 2012 2016-02-25 16:41:14Z RICHARD J STEPHENSON 1336 BASSWOOD ROAD SCHAUMBURG IL 60173 3280247 0 X DEMANDCURESTODAY.ORG X 1991 OK CANCER STUDY AND RESEARCH 15 15 0 0 0 0 2476644 3033342 0 0 21923 18209 0 0 2498567 3051551 1981500 1788480 0 0 0 0 0 0 0 2656 2393 1984156 1790873 514411 1260678 7090477 9911861 2535404 3814773 4555073 6097088 X TO FUND INNOVATIVE AND LIFE-CHANGING CLINICAL STUDIES THAT ACCELERATE NEW TREATMENT OPTIONS FOR CANCER PATIENTS. 0 0 1788480 1788480 GATEWAY FOR CANCER RESEARCH (FORMERLY KNOWN AS CANCER TREATMENT RESEARCH FOUNDATION OR CTRF), A NON-PROFIT 501(C)(3) ORGANIZATION, WAS ESTABLISHED IN 1991 TO PROMOTE RESEARCH THROUGH THE TREATMENT PROCESS AND SUPPORT PROGRESSIVE MOLECULAR, NUTRITIONAL AND IMMUNOLOGICAL RESEARCH PROGRAMS THAT MORE TRADITIONAL CANCER RESEARCH INSTITUTIONS MAY NOT FUND. GATEWAY IS DEDICATED TO ADVANCING INNOVATIONS IN THE SCIENTIFIC COMMUNITY AND SPEEDING THEM TO THE CANCER PATIENT'S BEDSIDE. THE WORK OF GATEWAY IS ABOUT GIVING CANCER PATIENTS THE ABILITY TO LIVE LONGER, MORE FULFILLING AND HEALTHIER LIVES.NO PORTION OF ANY PUBLIC CONTRIBUTION TO GATEWAY GOES TO FUNDRAISING OR ADMINISTRATIVE SALARIES. DUE TO GENEROUS CORPORATE UNDERWRITING OF ADMINISTRATIVE EXPENSES, 99% OF PUBLIC CONTRIBUTIONS RECEIVED ARE APPLIED DIRECTLY TO SUPPORT AGGRESSIVE CANCER RESEARCH AND SCIENTIFIC DEVELOPMENT PROGRAMS. OUR BOARD OF SCIENTIFIC COUNSELORS APPLIES STRINGENT GUIDELINES FOR REVIEWING EACH GRANT APPLICATION, RECOMMENDING TO THE BOARD OF DIRECTORS ONLY THOSE THAT ARE IN KEEPING WITH THE FOUNDATION'S MISSION. THROUGH THIS FORMAL REVIEW PROCESS, GATEWAY ENSURES THAT FUNDING IS GRANTED STRICTLY TO THOSE PROJECTS THAT ARE TRULY INNOVATIVE AND HAVE THE POTENTIAL TO QUICKLY TRANSLATE FROM THE RESEARCHER'S LABORATORY TO THE PATIENT'S BEDSIDE.AS THE NATION'S SECOND MOST DEADLY AND COSTLY DISEASE, CANCER RECOGNIZES NO BOUNDARIES. IN THE BATTLE AGAINST CANCER, GATEWAY IS ON THE FRONTLINES, SUPPORTING CLINICAL RESEARCH INITIATIVES DESIGNED TO ENHANCE QUALITY OF LIFE FOR CANCER PATIENTS, SURVIVORS, AND FAMILIES IN EVERY COMMUNITY NATIONWIDE. GATEWAY FOR CANCER RESEARCH HAS FUNDED OVER 100 CLINICAL TRIALS AND IS CURRENTLY FUNDING 26 INNOVATIVE RESEARCH PROJECTS DEALING WITH NEW AGENT STUDIES, IMMUNOLOGY, NUTRITION, AND GENE THERAPY. COMPARED TO OTHER ORGANIZTIONS OF OUR SIZE, WE ARE CLEARLY AMONG THE MOST SUCCESSFUL OF CANCER RESEARCH FOUNDATIONS. THE QUALITY OF OUR FUNDED RESEARCH CONTINUES TO IMPROVE EVERY YEAR AS WE RELENTLESSLY PURSUE THE MOST EXCITING PROSPECTS FOR CUTTING EDGE CLINICAL RESEARCH WITH IMPORTANT PATIENT IMPACT.BECAUSE WE ARE VIGILANT ABOUT MONITORING OUR CLINICAL RESEARCH STUDIES, WE CAN ASSURE OUR FUNDING PARTNERS THE BEST UTILIZATION OF THEIR CONTRIBUTIONS. WE IDENTIFY AND ENCOURAGE GREATER INTERACTION WITH OUR RESEARCHERS AND ENCOURAGE APPLICATIONS FROM CLINICAL INVESTIGATORS WHO CONSISTENTLY PROVIDE US WITH IMPORTANT PATIENT IMPACT RESEARCH.HISTORICAL DOCUMENTATION OF OUR RESEARCH PROJECTS PROVIDES A WINDOW THROUGH WHICH WE CAN VIEW OUR PAST ACCOMPLISHMENTS AND IMPLEMENT NEW STRATEGIC PROGRAMS THAT REFLECT OUR MISSION - TO FUND INNOVATIVE AND LIFE-CHANGING CLINICAL STUDIES THAT ACCELERATE NEW TREATMENT OPTIONS FOR CANCER PATIENTS. 1788480 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 1 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 29 0 0 0 0 0 0 0 1 1 0 0 0 0 X 15 15 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 AZ CA CO CT FL IL ME MD MA MI MN MT MO NH NJ NY NC OH OK PA RI SC TN TX VA WA WI X X DIANE KINSLER 8473427450 1336 BASSWOOD ROAD SCHAUMBURG IL 60173 X WAYNE DIXON 0.30 X 0 0 0 DOTTIE RZESZUTKO 0.30 X X 0 0 0 BRUCE LUBIN 0.30 X X 0 0 0 ROBERT MAYO 0.30 X 0 0 0 ROD MURRAY 0.30 X X 0 0 0 THOMAS DUENSING 0.30 X 0 0 0 MICHAEL T MULLINS 0.30 X X 0 0 0 RICHARD J STEPHENSON 0.30 X X 0 0 0 HARLAN TELLER 0.30 X 0 0 0 RHONDA KOKOT 0.30 X 0 0 0 MARY LOU SMITH 0.30 X 0 0 0 MICHAEL T CLUNE 0.30 X 0 0 0 SUSAN FLEMING 0.30 X 0 0 0 HEATHER LOWE 0.30 X 0 0 0 EDWIN ROBERSON 0.30 X 0 0 0 0 0 0 0 0 0 0 FAIRMONT HOTEL CHICAGO 200 N COLUMBUS DR CHICAGO IL 60601 GALA EVENT FACILITY SERVICES 137474 1 123985 2203618 705739 3033342 18209 18209 228696 2203618 228696 0 3051551 0 0 18209 1758480 1758480 30000 30000 MISCELLANEOUS 2393 2393 1790873 1788480 2393 0 1960202 714574 4859784 8877993 158352 110000 2539 109600 209294 7090477 9911861 292 2535404 3768961 45520 2535404 3814773 X 3947103 5494122 607970 602966 4555073 6097088 7090477 9911861 X 1260678 281337 X X 0 1 X 1 0 X 2050754 2161499 1891889 2476644 3033342 11614128 2050754 2161499 1891889 2476644 3033342 11614128 815177 10798951 31109 15754 19924 21923 18209 106919 11721047 9335125 0.92130 0.92580 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 X 5730965 2169381 281337 228696 2679414 3051551 0 3051551 4188950 2169381 228696 2398077 1790873 0 1790873 DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48: PART X, LINE 2: THE FOUNDATION EVALUATES ITS EXPOSURE FOR UNCERTAIN TAX POSITIONS ON AN ANNUAL BASIS. AS OF JUNE 30, 2013 AND 2012, THERE WERE NO LIABILITIES RELATED TO UNCERTAIN TAX POSITIONS. THE FEDERAL AND STATE RETURNS OF THE FOUNDATION FOR TAX YEARS 2009, 2010, AND 2011 ARE SUBJECT TO EXAMINATION BY THE INTERNAL REVENUE SERVICE AND STATE TAXING AUTHORITIES, GENERALLY FOR THREE YEARS AFTER THEY WERE FILED. PART XI, LINE 2D - OTHER ADJUSTMENTS: SPECIAL EVENT EXPENSES NETTED WITH FUNDS GENERATED 228,696. PART XII, LINE 2D - OTHER ADJUSTMENTS: SPECIAL EVENT EXPENSES NETTED WITH FUNDS GENERATED 228,696. SCHEDULE D, PARTS XII AND XIII, LINES 2D - AMOUNTS REPRESENT DIRECT EXPENSES FOR SPECIAL EVENTS HELD AND ARE REFLECTED IN PART VIII ON LINE 8B AGAINST REVENUES FROM FUNDRAISING EVENTS. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION GRANTS FOR CANCER RESEARCH 30000 0 0 0 0 0 0 30000 0 30000 EUROPE (INCLUDING ICELAND & GREENLAND) CANCER RESEARCH 30000 CASH 1 0 0 0 0 0 0 0 PROCEDURE FOR MONITORING GRANTS OUTSIDE THE U.S.: SCHEDULE F, PART I, LINE 2: PROCEDURES ARE THE SAME AS DOMESTIC GRANTS. SEE SCHEDULE I. GALA FUNDRAISER 2432314 2203618 228696 137474 91222 0 2432314 2203618 228696 137474 91222 228696 0 1 BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKING AVENUE BOSTON MA 02215 042103881 501(C)(3) 299607 CANCER RESEARCH CHILDREN'S HOSPITAL OF LOS ANGELES 4650 WEST SUNSET BOULEVARD LOS ANGELES CA 90027 951690977 501(C)(3) 155839 CANCER RESEARCH CHILDREN'S HOSPITAL OF PHILADELPHIA 3401 CIVIC CENTER BOULEVARD PHILADELPHIA PA 19104 231352166 501(C)(3) 266250 CANCER RESEARCH CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 953435919 501(C)(3) 66345 CANCER RESEARCH DUKE UNIVERSITY HEALTH SYSTEM 4020 NORTH ROXBORO STREET DURHAM NC 27704 562070036 501(C)(3) 228139 CANCER RESEARCH H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 12902 USF MAGNOLIA DRIVE TAMPA FL 33612 592451713 501(C)(3) 327594 CANCER RESEARCH RUSH UNIVERSITY MEDICAL CENTER 1653 WEST CONGRESS PARKWAY CHICAGO IL 60612 362174823 501(C)(3) 110780 CANCER RESEARCH WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501(C)(3) 303926 CANCER RESEARCH 8 0 PROCEDURE FOR MONITORING GRANTS IN THE U.S.: PART I, LINE 2: SCHEDULE I, PART I, LINE 2: ALL GRANT APPLICATIONS MUST GO THROUGH A RIGOROUS PEER REVIEW PROCESS LED BY OUR BOARD OF SCIENTIFIC COUNSELORS - A DISTINGUISHED BOARD OF RENOWNED SCIENTISTS, PHYSICIANS, AND RESEARCHERS. THROUGH THIS PROCESS, SCIENTISTS INCLUDING EXPERTS IN A PARTICULAR AREA OF CANCER REVIEW AND EVALUATE APPLICATIONS AGAINST A CAREFULLY PRESCRIBED SET OF CRITERIA FOR JUDGING THE SCIENTIFIC MERIT AND POTENTIAL VALUE OF EACH PROPOSED STUDY. THIS REVIEW, NOT ONLY INCLUDES A NUMERICAL GRADING OF OBJECTIVE CRITERIA BUT ALSO, INCLUDES A SUBJECTIVE COMMENTARY WITH SUGGESTED MODIFICATIONS. UPON RECOMMENDATION BY THE BOARD OF SCIENTIFIC COUNSELORS, THE APPLICATION IS SUBMITTED TO GATEWAY'S BOARD OF DIRECTORS FOR FUNDING CONSIDERATION. THE STRINGENT REVIEW PROCESS, DESCRIBED ABOVE, IS CONTINUED DURING THE COURSE OF THE STUDY, IF APPROVED AND FUNDED, WHEN REQUIRED PROGRESS REPORTS ARE SUBMITTED. THE PROGRESS REPORTS ARE REVIEWED BY THE BOARD OF SCIENTIFIC COUNSELORS AND RECOMMENDATIONS AND MODIFICATIONS ARE MADE, IF DEEMED NECESSARY, BY THE BOARD PRIOR TO PAYMENT OF ADDITIONAL FUNDS. BRUCE LUBIN CURRENT DIRECTOR OF GATEWAY FOR CANCER RESEARCH 2399611 MR. LUBIN IS AN OFFICER OF THE PRIVATEBANK AND TRUST CO. WHICH HOLDS CASH AND SHORT-TERM INVESTMENTS OF THE ORGANIZATION. 0 FORM 990, PART VI, SECTION B, LINE 11 FORM 990 IS FIRST REVIEWED BY THE ORGANIZATION'S INTERNAL STAFF AND A SUBSEQUENT REVIEW BY EXECUTIVE STAFF. THE FORM 990 IS THEN REVIEWED BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS AND SENT TO EACH CURRENT MEMBER OF THE BOARD FOR THEIR REVIEW AND ACTION. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION'S BOARD MEMBERS AND STAFF ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY DURING A REGULARLY SCHEDULED BOARD MEETING AND DURING THE STAFF MEMBERS ANNUAL PERFORMANCE EVALUATION MEETING. FORM 990, PART VI, SECTION C, LINE 19 THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC VIA IT'S WEBSITE AND OTHER NONPROFIT PUBLICATIONS. CHANGES IN NET ASSETS OR FUND BALANCES: FORM 990, PART XI, LINE 9: RETURN OF UNUSED GRANT FUNDS 281,337. FORM 990, PART XII, LINE 2C THE ORGANIZATION'S BOARD OF DIRECTORS ASSUMES RESPONSIBILITY FOR OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF AN INDEPENDENT ACCOUNTANT. THIS PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.